Last $85.70 USD
Change Today +0.38 / 0.45%
Volume 792.9K
EW On Other Exchanges
New York
As of 8:04 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

edwards lifesciences corp (EW) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/11/14 - $88.41
52 Week Low
12/13/13 - $60.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

edwards lifesciences corp (EW) Related Businessweek News

No Related Businessweek News Found

edwards lifesciences corp (EW) Details

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers surgical heart valve therapy products, such as tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve; and produces pericardial valves from biologically inert animal tissue. Its surgical heart valve therapy products include Carpentier-Edwards PERIMOUNT pericardial valve that comprise PERIMOUNT Magna Ease valves for aortic and mitral replacement; ThruPort systems that enable minimal incision valve surgery; and protection cannulae that is used during cardiac surgery in venous drainage, aortic perfusion, venting, and cardioplegia delivery. The company also provides transcatheter heart valves portfolio that includes technologies designed to treat heart valve disease using catheter-based approaches, as well as critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; Swan-Ganz line of pulmonary artery and PreSep continuous venous oximetry catheters for measuring central venous oxygen saturation; VolumeView sensor-catheters; FloTrac continuous cardiac output monitoring system, a minimally invasive cardiac monitoring technology for fluid optimization; and EV1000 clinical monitoring platform, which displays a patient's physiologic status. Its critical care products also include disposable pressure monitoring devices and closed blood sampling systems to help protect patients and clinicians from the risk of infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as balloon-tipped, catheter-based embolectomy products, surgical clips, and clamps. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

8,600 Employees
Last Reported Date: 02/28/14
Founded in 1999

edwards lifesciences corp (EW) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $879.8K
Corporate Vice President of Europe, Middle Ea...
Total Annual Compensation: $607.8K
Corporate Vice President of Critical Care & V...
Total Annual Compensation: $472.4K
Corporate Vice President of Heart Valve Thera...
Total Annual Compensation: $440.6K
Compensation as of Fiscal Year 2013.

edwards lifesciences corp (EW) Key Developments

Edwards Lifesciences Corporation Receives FDA Clearance for Advanced Noninvasive Monitoring System

Edwards Lifesciences Corporation announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system. The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used. Using a cuff on the outside of the finger that is connected to the Edwards EV1000 clinical platform, the ClearSight system: utilizes Edwards' proven, gold-standard monitoring technologies that are used in hospitals around the world, and incorporates a finger cuff and software elements that have been used for the noninvasive monitoring of the blood pressure of astronauts in space; automatically provides up-to-the-minute information without inserting anything into the body -- as compared to the traditionally more invasive approach to monitoring, which is only used in a fraction of those patients at risk of post-surgical complications; and thus provides an opportunity to extend the benefits of hemodynamic optimization, or proper fluid administration and balance within a patient's organs and tissues, to a broader patient population that could benefit from close monitoring, but may not receive it without a noninvasive option.

Edwards Lifesciences Corporation Launches SAPIEN XT Valve in US

Edwards Lifesciences Corporation has received United States Food and Drug Administration (FDA) approval for its Edwards SAPIEN XT transcatheter aortic heart valve for the treatment of high-risk and inoperable patients suffering from severe symptomatic aortic stenosis (AS). This next-generation, lower-profile system, which includes the 29mm valve size for patients with a large native annulus, will allow for the treatment of more patients. The Edwards SAPIEN XT valve will be immediately available to patients at few cardiovascular centers across the nation, along with the NovaFlex+ transfemoral delivery system that can be delivered through a low-profile 16-French expandable sheath (eSheath) and the Ascendra+ transapical and transaortic delivery systems. The Edwards SAPIEN XT valve has been commercially available in Europe since 2010, and received regulatory and reimbursement approval in Japan in 2013.

Edwards Lifesciences Corp. - Shareholder/Analyst Call

Annual General Meeting


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EW:US $85.70 USD +0.38

EW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $69.57 USD +0.93
Hologic Inc $25.23 USD +0.02
Mettler-Toledo International Inc $262.25 USD +7.51
Cooper Cos Inc/The $154.60 USD +2.46
Varian Medical Systems Inc $85.51 USD +1.24
View Industry Companies

Industry Analysis


Industry Average

Valuation EW Industry Range
Price/Earnings 31.0x
Price/Sales 4.4x
Price/Book 6.7x
Price/Cash Flow 29.2x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at